Abstract
361 Phase I, open-label, dose-escalating clinical and pharmacokinetic study of the novel antimicrotubulin agent PM060184 administered over 10 minutes on days 1-3 and 15-17 every 28 days to patients with advanced malignant solid tumors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have